Associated Papers
Association of ABCG2 Polymorphisms with Methotrexate Efficacy and Toxicity in Saudi Rheumatoid Arthritis Patients.
Sharawi ZW et al.
Pharmaceuticals (basel, Switzerland), 2025
Variants of the ABCG2 gene in Mexican mestizo patients with prostate cancer.
Mimendi-Aguilar GM et al.
Cellular and Molecular Biology (noisy-le-grand, France), 2025
Pharmacogenomics of response to statin treatment and susceptibility to statin-induced adverse drug reactions in Asians: a scoping review.
Yow HY et al.
Asian Biomedicine : Research, Reviews and News, 2023
Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer.
Veerman GDM et al.
Eclinicalmedicine, 2023
A meta-analysis and experimental data for multidrug resistance genes in breast cancer.
Zaib S et al.
African Health Sciences, 2022
Racial Disparity in Drug Disposition in the Digestive Tract.
Gao S et al.
International Journal of Molecular Sciences, 2021
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
Polymorphisms of genes encoding drug transporters or cytochrome P450 enzymes and association with clinical response in cancer patients: a systematic review.
Kulma I et al.
Cancer Chemotherapy and Pharmacology, 2019
Targeted next generation sequencing as a tool for precision medicine.
Gulilat M et al.
Bmc Medical Genomics, 2019
The contribution of ABCG2 G34A and C421A polymorphisms to multiple myeloma susceptibility.
Niebudek K et al.
Oncotargets and Therapy, 2019
Polymorphism of ABCG2 Gene in Hyperuricemia Patients of Han And Uygur Ethnicity with Phlegm/Non-Phlegm Block in Xinjiang, China.
Wang X et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 2018
Polymorphisms of ABCG2 and its impact on clinical relevance.
Zhang W et al.
Biochemical and Biophysical Research Communications, 2018
Interindividual Regulation of the Breast Cancer Resistance Protein/ABCG2 Transporter in Term Human Placentas.
Bircsak KM et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2018
Associations between ABCG2 gene polymorphisms and gefitinib toxicity in non-small cell lung cancer: a meta-analysis.
Tang L et al.
Oncotargets and Therapy, 2018
Assessment of Pharmacogenomic Panel Assay for Prediction of Taxane Toxicities: Preliminary Results.
Di Francia R et al.
Frontiers in Pharmacology, 2017
Multiple common and rare variants of ABCG2 cause gout.
Higashino T et al.
Rmd Open, 2017
Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters.
Matthaei J et al.
Genome Medicine, 2016
Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research.
Lewis T et al.
Clinical Pharmacology and Therapeutics, 2015
Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients.
Chen X et al.
Cancer Cell International, 2015
Genetic Variations in ABCG2 Gene Predict Breast Carcinoma Susceptibility and Clinical Outcomes after Treatment with Anthracycline-Based Chemotherapy.
Wu H et al.
Biomed Research International, 2015
Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2014
Impact of genetic variability in the ABCG2 gene on ABCG2 expression, function, and interaction with AT1 receptor antagonist telmisartan.
Deppe S et al.
Biochemical and Biophysical Research Communications, 2014
Fetal polymorphisms at the ABCB1-transporter gene locus are associated with susceptibility to non-syndromic oral cleft malformations.
Omoumi A et al.
European Journal of Human Genetics : Ejhg, 2013
A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis.
Campa D et al.
International Journal of Cancer, 2012
Gene polymorphisms of ABC transporters are associated with clinical outcomes in children with acute lymphoblastic leukemia.
Zhai X et al.
Archives of Medical Science : Ams, 2012
The contribution of the ABCG2 C421A polymorphism to cancer susceptibility: a meta-analysis of the current literature.
Chen P et al.
Bmc Cancer, 2012
Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
Tamura M et al.
Nagoya Journal of Medical Science, 2012
Prognostic value of the multidrug resistance transporter ABCG2 gene polymorphisms in Chinese patients with de novo acute leukaemia.
Wang F et al.
European Journal of Cancer (oxford, England : 1990), 2011
A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.
Pollack IF et al.
Neuro-oncology, 2011
ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations.
Kim KA et al.
Journal of Clinical Pharmacy and Therapeutics, 2010
Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with Acute Myeloid Leukemia.
Hampras SS et al.
International Journal of Molecular Epidemiology and Genetics, 2010
Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients.
Müller PJ et al.
International Journal of Cancer, 2009
Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy.
Kim DW et al.
Epilepsy Research, 2009
Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
Noguchi K et al.
Advanced Drug Delivery Reviews, 2009
Pharmacogenetic pathway analysis of irinotecan.
Rosner GL et al.
Clinical Pharmacology and Therapeutics, 2008
Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia.
Semsei AF et al.
Leukemia Research, 2008
The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects.
Adkison KK et al.
British Journal of Clinical Pharmacology, 2008
Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms.
Poonkuzhali B et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2008
Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.
Lemos C et al.
British Journal of Cancer, 2008
The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine.
Kim HS et al.
British Journal of Clinical Pharmacology, 2007
BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma.
Hu LL et al.
Carcinogenesis, 2007
The identification of two germ-line mutations in the human breast cancer resistance protein gene that result in the expression of a low/non-functional protein.
Yoshioka S et al.
Pharmaceutical Research, 2007
ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgeryin Hungarian patients with inflammatory bowel diseases.
Fischer S et al.
Scandinavian Journal of Gastroenterology, 2007
Concordance of pharmacogenetic polymorphisms in tumor and germ line DNA in adult patients with acute myeloid leukemia.
Weiss JR et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2007
Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study.
Anderson PL et al.
Journal of Acquired Immune Deficiency Syndromes (1999), 2006
Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development.
Yanase K et al.
Cancer Letters, 2006
[Functional SNPs of the breast cancer resistance protein (ABCG2) gene altering the pharmacokinetics/pharmacodynamics of anticancer agents].
Sugimoto Y
Seikagaku. the Journal of Japanese Biochemical Society, 2005
Pharmacogenetics for individualized cancer chemotherapy.
Efferth T et al.
Pharmacology & Therapeutics, 2005
Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics.
Sugimoto Y et al.
Cancer Science, 2005